List of Studies ( Metabolite:Dolichol-17)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST001066 | AN001744 | Lipidomics analysis for aged mice liver (part-III) | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001066 | AN001744 | Lipidomics analysis for aged mice liver (part-III) | Brain | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001066 | AN001744 | Lipidomics analysis for aged mice liver (part-III) | Liver | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001066 | AN001744 | Lipidomics analysis for aged mice liver (part-III) | Muscle | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001065 | AN001742 | Lipidomics analysis for aged mice brain cortex (part-II) | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001065 | AN001742 | Lipidomics analysis for aged mice brain cortex (part-II) | Brain | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001065 | AN001742 | Lipidomics analysis for aged mice brain cortex (part-II) | Liver | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001065 | AN001742 | Lipidomics analysis for aged mice brain cortex (part-II) | Muscle | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST000917 | AN001499 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000916 | AN001493 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000915 | AN001487 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000004 | AN000008 | Lipidomics studies on NIDDK / NIST human plasma samples | Blood | Human | LIPID MAPS | LC-MS |
